TY - JOUR
T1 - Golimumab and certolizumab
T2 - The two new anti-tumor necrosis factor kids on the block
AU - Mittal, Mohit
AU - Raychaudhuri, Siba P
PY - 2010/11
Y1 - 2010/11
N2 - Anti-tumor necrosis factor (anti-TNF) agents have revolutionized treatment of psoriasis and many other inflammatory diseases of autoimmune origin. They have considerable advantages over the existing immunomodulators. Anti-TNF agents are designed to target a very specific component of the immune-mediated inflammatory cascades. Thus, they have lower risks of systemic side-effects. In a brief period of 10 years, a growing number of biological therapies are entering the clinical arena while many more biologicals remain on the horizon. With time, the long-term side-effects and efficacies of these individual agents will become clearer and help to determine which ones are the most suitable for long-term care. Golimumab (a human monoclonal anti-TNF-α antibody) and Certolizumab (a PEGylated Fab fragment of humanized monoclonal TNF-α antibody) are the two latest additions to the anti-TNF regimen. Here, we are providing a brief description about these two drugs and their uses.
AB - Anti-tumor necrosis factor (anti-TNF) agents have revolutionized treatment of psoriasis and many other inflammatory diseases of autoimmune origin. They have considerable advantages over the existing immunomodulators. Anti-TNF agents are designed to target a very specific component of the immune-mediated inflammatory cascades. Thus, they have lower risks of systemic side-effects. In a brief period of 10 years, a growing number of biological therapies are entering the clinical arena while many more biologicals remain on the horizon. With time, the long-term side-effects and efficacies of these individual agents will become clearer and help to determine which ones are the most suitable for long-term care. Golimumab (a human monoclonal anti-TNF-α antibody) and Certolizumab (a PEGylated Fab fragment of humanized monoclonal TNF-α antibody) are the two latest additions to the anti-TNF regimen. Here, we are providing a brief description about these two drugs and their uses.
KW - Anti-tumor necrosis factor agents
KW - Certolizumab
KW - Golimumab
UR - http://www.scopus.com/inward/record.url?scp=78649296364&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78649296364&partnerID=8YFLogxK
U2 - 10.4103/0378-6323.72445
DO - 10.4103/0378-6323.72445
M3 - Article
C2 - 21079302
AN - SCOPUS:78649296364
VL - 76
SP - 602
EP - 609
JO - Indian Journal of Dermatology, Venereology and Leprology
JF - Indian Journal of Dermatology, Venereology and Leprology
SN - 0378-6323
IS - 6
ER -